Chengdu Kanghong Pharma 
Welcome,         Profile    Billing    Logout  
 3 Products   3 Diseases   3 Products   28 Trials   310 News 


«123456789»
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong
    Journal:  One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema. (Pubmed Central) -  Apr 23, 2020   
    The primary purpose was to investigate the effect and safety of conbercept, based on a practical protocol, in the eyes of patients with diabetic macular edema (DME), and the secondary aim was to evaluate the efficacy of low-dose triamcinolone acetonide in patients with refractory DME who had little response to conbercept...Conbercept could be effective for visual and anatomic improvements in DME eyes with relatively fewer intravitreal injections and longer treatment intervals in clinical practice. Low-dose TA may be useful for patients with refractory DME resistant to anti-VEGF therapy.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong
    Clinical, PK/PD data, Journal:  Intraocular Pharmacokinetics and Safety of Subretinal Injection Compared with Intravitreal Application of Conbercept in Vitrectomized Rabbit Eyes. (Pubmed Central) -  Apr 14, 2020   
    On the 28 day after injection, the drug level in the subretinal group was significantly higher than that in the intravitreal group in the AH (0.90 ± 0.25 μg/ml and 0.11 ± 0.07 μg/ml and 0.11 ± 0.07 P < 0.001, respectively) and the VH (5.00 ± 3.86 μg/ml and 0.11 ± 0.07 μg/ml and 0.11 ± 0.07 P < 0.001, respectively) and the VH (5.00 ± 3.86 P < 0.001, respectively) and the VH (5.00 ± 3.86 P < 0.001, respectively) and the VH (5.00 ± 3.86 . Our study indicates that applying conbercept by subretinal injection can reduce the drug clearance rate and sustain a long maintenance period in ocular tissue, which suggests that subretinal conbercept injection may be a potentially valuable treatment option.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong
    The proteomic profiles in aqueous humor of patients with neovascular age-related macular degeneration. (Exhibit Hall: Posterboard# B0242) -  Mar 9, 2020 - Abstract #ARVO2020ARVO_5783;    
    Purpose To explore top-ranked aqueous humor proteins and identify specific biomarkers related to neovascular age-related macular degeneration (nAMD) and explore pathways related to neovascular AMD.Methods Eighteen nAMD patients initially treated with an intravitreal injection of Ranicizumab or Conbercept and ten age- and sex-matched cataract controls were studied.The proteome of 28 aqueous humor samples was analyzed by liquid chromatography coupled mass spectrometry...The described pathways specific for the nAMD patient groups and the identification of characteristic differentially regulated proteins provide a first step toward the definition of biomarkers for nAMD. The presented data will facilitate the investigation of mechanistic connections of proteins to the respective disease.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  A Multinational Comparison of Anti-Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific. (Pubmed Central) -  Dec 20, 2019   
    Outside of the United States, many nations are using a majority of more expensive anti-VEGF medications, which may lead to increased costs and decreased access. Increasing the availability of safely compounded anti-VEGF medications will likely improve access, create patient/provider choice, and decrease relative healthcare costs for the growing burden of retinal diseases globally.
  • ||||||||||  conbercept (KH902) / Chengdu Kanghong
    Conbercept, first results (RED Hall) -  Dec 5, 2019 - Abstract #OCTA2019OCTA_70;    
  • ||||||||||  conbercept (KH902) / Chengdu Kanghong
    Journal:  Conbercept and Retinal Photocoagulation in the treatment of Diabetic Macular Edema. (Pubmed Central) -  Dec 1, 2019   
    There were no severe eye complications and systemic adverse reactions in both groups in the process of follow up. Intravitreal injection of conbercept in combination with retinal laser photocoagulation performs better in improving the BCVA and central macular thickness of patients with diabetic macular edema compared to retinal laser photocoagulation and has high safety.
  • ||||||||||  nesvacumab (REGN910) / Regeneron
    Journal:  Innovative therapies for neovascular age-related macular degeneration. (Pubmed Central) -  Nov 24, 2019   
    Sustained-release anti-VEGF treatments, to address treatment burden, include the ranibizumab Port Delivery System, GB-102, NT-503, hydrogel depot, Durasert, and ENV1305. Similarly, genetic therapies, including RGX-314 and ADVM-022, aim to provide sustained anti-VEGF expression from the retina.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Trial completion, Enrollment change:  Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy (clinicaltrials.gov) -  Nov 21, 2019   
    P4,  N=112, Completed, 
    Similarly, genetic therapies, including RGX-314 and ADVM-022, aim to provide sustained anti-VEGF expression from the retina. Recruiting --> Completed | N=30 --> 112
  • ||||||||||  conbercept (KH902) / Chengdu Kanghong
    Journal:  A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity. (Pubmed Central) -  Oct 29, 2019   
    Follow-up continued until 90 weeks' postmenstrual age and showed no recurrences of plus disease or neovascularization. The study suggests 0.15 mg IVC is effective for Zone II Stage 2/3 + ROP, and there is no adverse ocular outcomes during the follow-up period.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, conbercept (KH902) / Chengdu Kanghong
    Comparison of short-term efficacy between conbercept and ranibizumab for treatment of myopic choroidal neovascularization () -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1260;    
    The study showed functional and anatomical improvement after treatment of conbercept and ranibizumab for myopic CNV during a 6-month follow-up period, but conbercept may be more effective than ranibizumab in promoting CFT reduction and CNV lesion reduction at 1 month after intravitreal injection and it may have a fewer injections than ranibizumab. A larger, longer period and randomized double shamed study is required to determine the efficacy of these two drugs.
  • ||||||||||  conbercept (KH902) / Chengdu Kanghong
    Altered vitreous microRNA expression profile after intravitreal conbercept in proliferative diabetic retinopathy () -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_800;    
    Intraocular injection of conbercept combined with 23G vitrectomy for the treatment of proliferative diabetic retinopathy can complete the operation more quickly, reduce the intraoperative photocoagulation usage rate and reduce postoperative complications. The current study implies that there was a vitreous specific miRNA expression profile after intravitreal conbercept in PDR, and vitreous miR-205-5p and miR-124-3p.1 were significantly up-regulated after intravitreal conbercept in PDR via targeting VEGF and PlGF.
  • ||||||||||  conbercept (KH902) / Chengdu Kanghong
    Correlation of retinal layer changes with vision gain in diabetic macular edema during conbercept treatment () -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_756;    
    Whereas the largest decrease of layer thickness occurred in the INL and ONL, the decreases in GCL and IPL were more associated with gains in vision and improved microperimetry. The decrease of the GCL and IPL might suggest that neural recovery occurred after the resolution of edema during conbercept treatment.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, conbercept (KH902) / Chengdu Kanghong
    Retrospective data, Review, Journal:  Comparison of conbercept and ranibizumab for the treatment efficacy of diabetic macular edema: a Meta-analysis and systematic review. (Pubmed Central) -  Sep 25, 2019   
    Pooled evidence suggests that both IVC and IVR are effective in the therapy of diabetic macular edema and affirms that IVC presents superiority over IVR therapy in regard of CMT in patients with diabetic macular edema, but no statistically significant difference with regard to visual improvement. Relevant RCTs with longer-term follow-up are necessary to back up our conclusion.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Pharmacology study of a chimeric decoy receptor trap fusion protein on retina neovascularization by dual blockage of VEGF and FGF-2. (Pubmed Central) -  Aug 30, 2019   
    The in vivo pharmacological studies demonstrated that the incidence of CNV formation was largely reduced in RC28 treatment groups with a low dosage as compared to other VEGF antagonist control groups. Furthermore, traces of RC28 were detected as dispersing from eyeballs to the liver after 20 days, and a prolonged half-time pharmacokinetic profile was exhibited.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, conbercept (KH902) / Chengdu Kanghong
    Journal:  One-Year Outcomes of Intravitreal Conbercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration. (Pubmed Central) -  Aug 3, 2019   
    OCTA enables non-invasive, layer-specific and quantitative assessment of microvascular changes in eyes with BRVO before and after treatment, and it can be used as a valuable imaging tool for the evaluation of the follow-up in BRVO patients. Intravitreal injections of conbercept appear to be beneficial in patients with nvAMD who exhibit persistent fluid despite previous treatment with ranibizumab.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma, Visudyne (verteporfin) / Novartis
    Trial completion, Trial completion date, Combination therapy:  Initial Versus Delayed PDT Combination With Conbercept in PCV (clinicaltrials.gov) -  Jul 18, 2019   
    P4,  N=80, Completed, 
    No abstract available Recruiting --> Completed | Trial completion date: Dec 2019 --> Jun 2019